Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.
Krupka C, et al. Among authors: pombo villar e.
Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060.
Oncotarget. 2017.
PMID: 28415689
Free PMC article.